Product Description
AR-882 is being developed by Arthrosi Therapeutics for the treatment of gout. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04155918?term=AR-882&draw=2&rank=1)
Mechanisms of Action: URAT1 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Fast Track - Gout *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Arthrosi Therapeutics
Company Location: Western America
Company Founding Year: 2016
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China, Hong Kong, New Zealand, Taiwan, United States
Active Clinical Trial Count: 6
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Gout
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12623001038684 |
ACTRN12623001038684 | P1 |
Completed |
Gout |
2024-07-16 |
2026-02-15 |
Treatments |
|
NCT07116746 |
AR882-204 | P2 |
Active, not recruiting |
Unknown |
2026-11-01 |
50% |
2026-05-16 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT05253833 |
AR882-203 | P2 |
Completed |
Unknown |
2024-08-13 |
2024-11-14 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT06846515 |
AR882-301 | P3 |
Active, not recruiting |
Unknown |
2026-09-01 |
5% |
2026-05-13 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT06603142 |
APRAB-H001-P301 | P3 |
Active, not recruiting |
Unknown |
2026-04-01 |
2024-09-20 |
Primary Endpoints |
|
NCT06439602 |
AR882-302 | P3 |
Completed |
Unknown |
2026-03-20 |
5% |
2026-05-14 |